Cargando…

Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact

BACKGROUND: Meningococcal disease remains an important cause of morbidity and mortality worldwide. The first broadly effective vaccine against group B disease (which causes considerable meningococcal disease in Europe, the Americas and Australasia) was licensed in the EU in January 2013; our objecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Christensen, Hannah, Hickman, Matthew, Edmunds, W. John, Trotter, Caroline L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743045/ https://www.ncbi.nlm.nih.gov/pubmed/23566946 http://dx.doi.org/10.1016/j.vaccine.2013.03.034

Ejemplares similares

Meningococcal serogroup B vaccines: Estimating breadth of coverage
por: Donald, Robert G. K., et al.
Publicado: (2016)

Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013
por: Gamougam, Kadidja, et al.
Publicado: (2015)

Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine
por: Tzanakaki, Georgina, et al.
Publicado: (2014)

Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B
por: Rivero-Calle, Irene, et al.
Publicado: (2019)

2457. Multivariate Analyses of Socio-Economic Inequities in Parental Awareness and Utilization of Meningococcal Serogroup B Vaccines
por: Huang, Liping, et al.
Publicado: (2018)

Estimation of the Impact of Meningococcal Serogroup C Universal Vaccination in Italy and Suggestions for the Multicomponent Serogroup B Vaccine Introduction
por: Martinelli, Domenico, et al.
Publicado: (2015)

Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study
por: Christensen, Hannah, et al.
Publicado: (2014)

01. Serum Bactericidal Activity Against Circulating and Reference Strains of Meningococcal Serogroup B in the United States: A Review of Meningococcal Serogroup B (MenB) Vaccines in Adolescents and Young Adults
por: Coyne-Beasley, Tamera, et al.
Publicado: (2021)

Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study
por: Daugla, DM, et al.
Publicado: (2013)

Toward an Improved Meningococcal Serogroup B Assay
por: Poolman, Jan
Publicado: (2018)

Are physicians obligated to tell parents about the meningococcal serogroup B vaccine?
por: Robinson, Dr Joan L
Publicado: (2015)

Parental awareness and utilization of meningococcal serogroup B vaccines in the United States
por: Srivastava, Amit, et al.
Publicado: (2020)

The Serogroup B Meningococcal Vaccine Bexsero Elicits Antibodies to Neisseria gonorrhoeae
por: Semchenko, Evgeny A, et al.
Publicado: (2019)

Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits
por: Stawasz, Andrew, et al.
Publicado: (2020)

The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology
por: Racloz, Vanessa N, et al.
Publicado: (2010)

Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults
por: Presa, Jessica, et al.
Publicado: (2023)

Meningococcal disease serogroup C
por: Dickinson, Félix O, et al.
Publicado: (2012)

Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015
por: Folaranmi, Temitope, et al.
Publicado: (2015)

Invasive Meningococcal Disease and Meningococcal Serogroup B Vaccination in Adults and Their Offspring: Knowledge, Attitudes, and Practices in Italy (2019)
por: Riccò, Matteo, et al.
Publicado: (2023)

Four-Component Recombinant Protein–Based Vaccine Effectiveness Against Serogroup B Meningococcal Disease in Italy
por: Lodi, Lorenzo, et al.
Publicado: (2023)

An Unexpected Fever Post Serogroup B Meningococcal Sepsis
por: Donà, Daniele, et al.
Publicado: (2016)

Recent Progress in the Prevention of Serogroup B Meningococcal Disease
por: Feavers, Ian M., et al.
Publicado: (2017)

Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives
por: SIGNORELLI, C., et al.
Publicado: (2015)

2. Understanding Patient Preferences for Meningococcal Serogroup B Vaccines in the United States
por: Johnson, Reed, et al.
Publicado: (2020)

A comparison of national vaccination policies to prevent serogroup B meningococcal disease
por: Sulis, Giorgia, et al.
Publicado: (2022)

Serogroup Y Meningococcal Disease, Colombia
por: Agudelo, Clara Inés, et al.
Publicado: (2008)

Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine
por: Marjuki, Henju, et al.
Publicado: (2019)

Meningococcal serogroup B disease in Turkey: A guess or reality?
por: Bakir, Mustafa
Publicado: (2014)

Spatiotemporal Analysis of Serogroup C Meningococcal Meningitis Spread in Niger and Nigeria and Implications for Epidemic Response
por: Cooper, Laura V, et al.
Publicado: (2019)

Progressive Decrease in the Potential Usefulness of Meningococcal Serogroup B Vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain
por: Pérez-Trallero, Emilio, et al.
Publicado: (2014)

Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil
por: Tauil, Márcia de Cantuária, et al.
Publicado: (2014)

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK
por: Hadley, Liza, et al.
Publicado: (2023)

Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease
por: Hedari, Carine P, et al.
Publicado: (2014)

Serogroup X in Meningococcal Disease, Western Kenya
por: Materu, Sadiki, et al.
Publicado: (2007)

A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program
por: O’Ryan, Miguel, et al.
Publicado: (2013)

Serogroup B Meningococcal Disease Vaccine Recommendations at a University, New Jersey, USA, 2016
por: Soeters, Heidi M., et al.
Publicado: (2017)

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK – ERRATUM
por: Hadley, Liza, et al.
Publicado: (2023)

US College Students Are at Increased Risk for Serogroup B Meningococcal Disease
por: Marshall, Gary S, et al.
Publicado: (2019)

Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine
por: van Ravenhorst, Mariëtte B., et al.
Publicado: (2018)

Endogenous complement human serum bactericidal assay (enc-hSBA) for vaccine effectiveness assessments against meningococcal serogroup B
por: Kleinschmidt, Annett, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hp1htepsjdt67j7enl0f8ppb1d